WellMed and GlaxoSmithKline to develop online herpes risk assessment tool
The partners believe the development of the tool is an important step toward educating individuals about the risk of contracting herpes while focusing on reducing the negative stigma associated with the disease. Genital herpes is one of the most common sexually transmitted diseases, estimated to affect more than 50 million people in the United States alone.
WellMed offers online management tools that provide pharmaceutical companies with direct-to-consumer relationship management programs. In addition, its health assessment, disease tracking and medication compliance modules, condition-specific evaluation programs and health improvement programs are designed to offer clinically based treatment information and decision-support systems, to help users explore therapeutic options for specific medical conditions.
"We are delighted to join forces with one of the largest pharmaceutical companies in the world for the development of an innovative awareness program that educates individuals about how to live with this common disease," said Craig Froude, President and CEO of WellMed. "WellMed's strength lies in using technology to communicate important and relevant health information in a private and secure environment. Working with research-based pharmaceutical companies, like GlaxoSmithKline, helps us deliver important information about treatment options to the people who need it most."